S'abonner

RETRACTED: A Four-Year Randomized Controlled Trial of Hormone Replacement and Bisphosphonate, Alone or in Combination, in Women with Postmenopausal Osteoporosis - 09/09/11

Doi : 10.1016/S0002-9343(98)00029-1 
Sunil J Wimalawansa A,
A Department of Medicine, Royal Postgraduate Medical School, London, England, United Kingdom. 

*Sunil J. Wimalawansa, MD, PhD, Professor of Medicine, Department of Internal Medicine, Divisions of General Medicine and Endocrinology, The University of Texas Medical Branch at Galveston, 8.104 Medical Research Building, 301 University Boulevard, Galveston, Texas 77555-1065.Department of Internal MedicineDivisions of General Medicine and EndocrinologyThe University of Texas Medical Branch at Galveston8.104 Medical Research Building301 University BoulevardGalvestonTexas77555-1065

Résumé

This article has been retracted: please see Elsevier Policy on Article Withdrawal (withdrawalpolicy).

This article is being retracted at the request of the Editor in Chief because of the stated concerns listed below. The author was contacted to provide information related to concerns about governance, ethical oversight, authorship and location of study. As this information was not fully provided and the response received not sufficient, the concern with regard to the integrity of the publication remains and the article will be retracted.

In addition, the Research Integrity Office at Imperial College London was contacted for comment and responded that they were not able to locate information related to the clinical trial to investigate further. However, Imperial College noted that the article was published several years after the author had left Royal Postgraduate Medical School and it is unlikely that the author would have been solely responsible for the research reported in this single-authored paper. They noted that concerns raised regarding the article appear to be well-founded.

Research governance

• No details of the source(s) of funding were provided for the 4-year clinical trial.

• Study location was not specified in the article.

Ethics

• The name of the ethics committee which approved the study was not reported.

Authorship

• Discrepancies between author’s reported institutional affiliations and the timing of his employment at that institution, such that he was the sole author on a publication that describes a 4-year clinical trial published in 1998 yet had left the institution at which the work was said to have been conducted 4 years earlier.

Productivity

• Only 1 researcher for the conduct of complicated and labour-intensive 4-year clinical trial.

Research conduct

• Dates during which the studies took place are not reported.

• Recruitment and follow-up workload seem implausible for a single investigator.

Statistics and data

• Baseline summary data in randomized groups seem implausibly similar.

• There was an implausibly high frequency of identical summary data in randomized groups.

• Variances in several variables were implausibly small.

• There were discrepancies between reported whole group mean values and those calculated from reported subgroup data.

• Fracture data contains errors and outcomes are implausible.

• Fractures are implausibly more frequent at vertebral than non-vertebral sites.

• Implausible rates of height loss are reported.

Le texte complet de cet article est disponible en PDF.

© 1998  Elsevier Science Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 104 - N° 3

P. 219-226 - mars 1998 Retour au numéro
Article précédent Article précédent
  • Discussion
| Article suivant Article suivant
  • A Randomized, Double-Blind, Placebo-controlled Study of Growth Hormone in the Treatment of Fibromyalgia
  • Robert M Bennett, Sharon C Clark, Jacqueline Walczyk

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.